All In Biotech

Drug Trial Radar · NCT05353361

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

A Phase Ib/II Multicenter, Open-Label Clinical Trial of SHR-A1811 Injection in Combination With Pyrotinib or Pertuzumab or Adebrelimab or Paclitaxel for Injection (Albumin Bound) in Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

402

Planned (sponsor's estimate)

Start

May 23, 2022

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.

Conditions

  • Breast Cancer

Interventions

  • SHR-A1811:PyrotinibDrug

    SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib:Tablet, 160mg / tablet, 80mg / tablet, oral

  • SHR-A1811;PertuzumabDrug

    SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab:Injection, 420 Mg (14 ml) / bottle, intravenous drip

  • SHR-A1811;AdebrelimabDrug

    SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab:Injection, 12ml: 0.6g/bottle, intravenous drip

  • SHR-A1811;Albumin paclitaxelDrug

    SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel:Injection, 100mg / box, intravenous drip

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT(Phase I (dose exploration phase) )Time frame: 21 days after the first administration of each subject
  2. AE(Phase I (dose exploration phase) )Time frame: from Day1 to 40 or 90 days after last dose
  3. Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) )Time frame: from Day1 to 40 or 90 days after last dose
  4. Objective response rate(Phase II (efficacy expansion phase))Time frame: Two years after the last subject was enrolled in the group

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.